5 results match your criteria: "Phoenix Creighton University[Affiliation]"
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary.
Future Oncol
October 2024
HonorHealth Research Institute, University of Arizona College of Medicine, Phoenix Creighton University, Phoenix, AZ, USA, when the study was conducted; present affiliation GOG Foundation; Florida Cancer Specialists & Research Institute, West Palm Beach, FL, USA.
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
Eur J Cancer
August 2023
HonorHealth Research Institute, University of Arizona College of Medicine, Phoenix Creighton University, Phoenix, AZ, USA.
Article Synopsis
- The study reports long-term efficacy and safety of niraparib in patients with advanced ovarian cancer after first-line chemotherapy, comparing it to a placebo in a phase 3 trial.
- With a median follow-up of 3.5 years, patients receiving niraparib showed significantly longer progression-free survival (PFS) compared to those on placebo, particularly in patients with homologous recombination deficiency (HRd).
- While the treatment was associated with some serious side effects like thrombocytopenia and anemia, the long-term benefits of niraparib in delaying disease progression were evident, suggesting its potential as a strong option for this patient group.
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
Gynecol Oncol
February 2022
University of Arizona College of Medicine, Phoenix Creighton University School of Medicine at St. Joseph's Hospital, Phoenix, AZ, USA. Electronic address:
Background: Age and ethnicity are among several factors that influence overall survival (OS) in ovarian cancer. The study objective was to determine whether ethnicity and age were of prognostic significance in women enrolled in a clinical trial evaluating the addition of bevacizumab to front-line therapy.
Methods: Women with advanced stage ovarian, primary peritoneal, or fallopian tube cancer were enrolled in a phase III clinical trial.
Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study.
Br J Cancer
January 2018
Department of Pathology (SL) and Department of Gynecologic Oncology (KT), Irvine Medical Center, University of California, Orange, CA 92868, USA.
Background: Based primarily on studies concerning early-stage tumours (treated surgically), and locally advanced disease (treated with chemoradiation), the prognosis for women with adenocarcinoma (AC) or adenosquamous (AS) carcinoma has been reported to be poorer than those with squamous cell carcinoma (SCCA) of the cervix. It is unclear whether differences in prognosis also persist in the setting of recurrent or metastatic disease treated using chemotherapy doublets with or without bevacizumab.
Methods: Cases were pooled from three Gynaecologic Oncology Group randomised phase III trials of chemotherapy doublets.
In vitro chemoresponse in metachronous pairs of ovarian cancers.
Anticancer Res
December 2014
University of Arizona Cancer Center-Phoenix Creighton University School of Medicine at St. Joseph's, Department of Obstetrics and Gynecology, Phoenix, AZ, U.S.A.
Background/aim: An in vitro chemoresponse assay may aid effective therapy selection in epithelial ovarian cancer (EOC). This study explores changes in chemoresponse between paired primary and recurrent EOC tumors.
Patients And Methods: RESULTS from metachronous tumors were examined in 242 patients.